CRDF - Cardiff Oncology GAAP EPS of -$0.25 misses by $0.02 revenue of $0.08M beats by $0.02M
2023-05-04 17:41:13 ET
- Cardiff Oncology press release ( NASDAQ: CRDF ): Q1 GAAP EPS of -$0.25 misses by $0.02 .
- Revenue of $0.08M (+14.3% Y/Y) beats by $0.02M .
-
As of March 31, 2023, Cardiff Oncology had approximately $97.0 million in cash, cash equivalents, and short-term investments.
-
Net cash used in operating activities for the first quarter of 2023 was approximately $8.7 million, a decrease of approximately $1.5 million from $10.2 million for the same period in 2022.
For further details see:
Cardiff Oncology GAAP EPS of -$0.25 misses by $0.02, revenue of $0.08M beats by $0.02M